HLS Therapeutics (TSE:HLS) Hits New 1-Year Low – What’s Next?

HLS Therapeutics Inc. (TSE:HLS)’s stock price reached a new 52-week low on Friday . The stock traded as low as C$3.00 and last traded at C$3.51, with a volume of 33000 shares trading hands. The stock had previously closed at C$3.84.

Wall Street Analyst Weigh In

Separately, Stifel Nicolaus cut their price objective on shares of HLS Therapeutics from C$3.75 to C$3.25 in a report on Tuesday, August 13th.

HLS Therapeutics Price Performance

The company’s 50-day moving average price is C$3.48 and its two-hundred day moving average price is C$3.71. The company has a market cap of C$111.58 million, a P/E ratio of -3.31 and a beta of 1.07. The company has a current ratio of 2.02, a quick ratio of 1.01 and a debt-to-equity ratio of 100.44.

HLS Therapeutics (TSE:HLS) last announced its quarterly earnings data on Thursday, August 8th. The company reported C($0.25) earnings per share for the quarter, meeting analysts’ consensus estimates of C($0.25). HLS Therapeutics had a negative net margin of 40.90% and a negative return on equity of 24.82%. The business had revenue of C$19.87 million during the quarter, compared to the consensus estimate of C$19.25 million. As a group, sell-side analysts expect that HLS Therapeutics Inc. will post -0.12 earnings per share for the current year.

About HLS Therapeutics

HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company’s product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease.